Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13871MR)

This product GTTS-WQ13871MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13871MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3602MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ5199MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ2899MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ14812MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ6851MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ2553MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ9836MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ9116MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN242
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW